AstraZeneca extended its license to Linguamatics’ I2E interactive information extraction system with a further multiyear deal. The company has been a customer of Linguamatics since 2003. I2E uses natural language processing-based text-mining technology to provide insights from literature sources in real-time. The platform supports decision making at many points in the drug discovery process including target selection, biomarker discovery, and safety/toxicology.

Previous articlePresident Obama Plans to Nominate Francis Collins as NIH Director
Next articleEndo Pays $20M Up Front for Bioniche’s Late-Stage Bladder Cancer Treatment